Value
9.0/10data confidence 33%| Component | Sub-score |
|---|---|
| Analyst target | 9.0 |
- ▸Attractively valued
SLN · Why this verdict
Why Silence Therapeutics Plc - Amer (SLN) is rated SELL
Updated
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
VerdictSELL
Overall score6.6/10
ConfidenceMEDIUM
MacroNEUTRAL
Thesis pillars
| Pillar | Expectation | Trend |
|---|---|---|
The business is burning cash at an extreme rate, with free cash flow at -5442% of revenue, and fails the Rule of 40 test by a wide margin. Quality breakdown | Free cash flow burn as a percentage of revenue should narrow materially, and the Rule of 40 score should improve within 12 months. | →Stable |
| CounterA single large R&D or trial expense could distort the free cash flow ratio without reflecting a structural burn problem. | ||
Revenue grew 197% year-over-year, and the peer comparison notes flag the company as an industry growth leader. Growth breakdown | Year-over-year revenue growth should stay above 50% over the next several quarters if the growth trajectory holds. | →Stable |
| CounterHyper-growth off a small base is often unsustainable and could decelerate sharply as comparisons normalize. | ||
The engine measures a favorable 9.62x asymmetry ratio with 144.2% upside potential against a 7% downside stop, even as RSI sits at an overbought 81. Reward-to-risk math | Price should progress toward the $25.38 take-profit target over the next 12 months if the asymmetric setup resolves favorably. | →Stable |
| CounterAn RSI reading of 81 signals an overbought condition that frequently precedes a near-term pullback before any further advance. | ||
The put/call ratio is elevated at 5.50, indicating market participants are hedging or positioning for downside risk despite bullish price action. Risk breakdown | The put/call ratio should normalize toward 1.0 or below if bearish hedging pressure eases. | →Stable |
| CounterA high put/call ratio can also reflect protective hedging by long holders rather than a genuinely bearish market view. | ||
The company has split evenly on earnings over the last 4 quarters, with an average surprise of -90.25%, reflecting high volatility in reported results. Earnings | The beat/miss ratio should improve to a majority-beat pattern with a less volatile average surprise if forecasting improves. | →Stable |
| CounterClinical-stage biotech earnings are inherently lumpy, and volatility in surprise percentages does not necessarily indicate deteriorating fundamentals. | ||
The business is burning cash at an extreme rate, with free cash flow at -5442% of revenue, and fails the Rule of 40 test by a wide margin.
→StableQuality breakdown
- Expectation
- Free cash flow burn as a percentage of revenue should narrow materially, and the Rule of 40 score should improve within 12 months.
CounterA single large R&D or trial expense could distort the free cash flow ratio without reflecting a structural burn problem.
Revenue grew 197% year-over-year, and the peer comparison notes flag the company as an industry growth leader.
→StableGrowth breakdown
- Expectation
- Year-over-year revenue growth should stay above 50% over the next several quarters if the growth trajectory holds.
CounterHyper-growth off a small base is often unsustainable and could decelerate sharply as comparisons normalize.
The engine measures a favorable 9.62x asymmetry ratio with 144.2% upside potential against a 7% downside stop, even as RSI sits at an overbought 81.
→StableReward-to-risk math
- Expectation
- Price should progress toward the $25.38 take-profit target over the next 12 months if the asymmetric setup resolves favorably.
CounterAn RSI reading of 81 signals an overbought condition that frequently precedes a near-term pullback before any further advance.
The put/call ratio is elevated at 5.50, indicating market participants are hedging or positioning for downside risk despite bullish price action.
→StableRisk breakdown
- Expectation
- The put/call ratio should normalize toward 1.0 or below if bearish hedging pressure eases.
CounterA high put/call ratio can also reflect protective hedging by long holders rather than a genuinely bearish market view.
The company has split evenly on earnings over the last 4 quarters, with an average surprise of -90.25%, reflecting high volatility in reported results.
→StableEarnings
- Expectation
- The beat/miss ratio should improve to a majority-beat pattern with a less volatile average surprise if forecasting improves.
CounterClinical-stage biotech earnings are inherently lumpy, and volatility in surprise percentages does not necessarily indicate deteriorating fundamentals.
TrendMatrix Research · core thesis
Engine thesis — one sentence
Silence Therapeutics combines explosive revenue growth and an engine-favored asymmetric setup with severe cash burn and volatile earnings, making it a high-risk, high-reward growth story.
Falsifiable statement — pillar-level invalidators below. Engine-derived; not personalized advice.
Per-dimension breakdown
Quality
3.5/10data confidence 100%| Component | Sub-score |
|---|---|
| ROE | 0.0 |
| ROA | 0.0 |
| Gross margin | 10.0 |
| Net margin | 0.0 |
| Current ratio | 5.0 |
| FCF quality | 0.0 |
| Moat | 7.2 |
| Rule of 40 | 3.0 |
| Piotroski F | 6.7 |
- ▸Cash-burning: FCF -5442% of revenue
- ▸Rule of 40: -5244 (fail)
Growth
10.0/10data confidence 33%| Component | Sub-score |
|---|---|
| Rev growth | 10.0 |
- ▸Strong growth: 197% YoY
Momentum
7.6/10data confidence 100%| Component | Sub-score |
|---|---|
| RSI | 4.0 |
| MACD | 10.0 |
| OBV | 10.0 |
| MA position | 9.0 |
| Volume | 4.8 |
- ▸Overbought (RSI 81)
- ▸Volume accumulation (rising OBV)
- ▸Above 200-day MA
Sentiment
8.1/10data confidence 67%| Component | Sub-score |
|---|---|
| Analyst rating | 6.6 |
| Price target | 10.0 |
- ▸Light analyst coverage (6.0) — signal dampened
- ▸Analyst upside: 181%
Insider
5.3/10data confidence 50%| Component | Sub-score |
|---|---|
| materiality | 5.0 |
| holder change | 5.6 |
- ▸No net insider activity — $0 (0.000% of mkt cap)
Peer rank
5.7/10data confidence 80%| Component | Sub-score |
|---|---|
| value rank | 5.0 |
| quality rank | 0.2 |
| growth rank | 9.4 |
- ▸Industry growth leader
- ▸Conservative debt levels
Technical
4.2/10data confidence 100%| Component | Sub-score |
|---|---|
| bollinger | 1.7 |
| support resistance | 1.3 |
| 52w position | 8.8 |
| gap | 5.0 |
Risk (lower is worse)
3.8/10data confidence 100%| Component | Sub-score |
|---|---|
| short interest | 7.1 |
| days to cover | 1.4 |
| volatility | 0.0 |
| put call | 0.0 |
| beta | 5.5 |
| debt equity | 8.9 |
- ▸Elevated put/call: 5.50
Catalyst
2.8/10data confidence 75%| Component | Sub-score |
|---|---|
| earnings history | 3.3 |
| earnings timing | 5.0 |
| surprise avg | 0.0 |
- ▸Earnings concerns: 2B/2M
How the verdict was assembled
Engine trigger
Quality below minimum threshold.
Engine technical detail
verdict_path:
L1:HARD_BLOCKPassed (8)
- MOMENTUM:7.6>=5.5
- ASYMMETRY:9.6>=1.5
- INSIDER:OK
- 8K:CLEAN
- NEWS_EVENTS:NONE_RECENT
- EARNINGS_PROXIMITY:33d clear
- SEMI_CYCLE_PEAK:CLEAR
- MATERIALS_CYCLE_PEAK:CLEAR
Failed (0)
none
Warning (0)
none
Reward-to-Risk
9.62
Upside
+144.2%
Downside
15.0%
Sizing output
AVOID
Setup— — No clear chart pattern; technical signals are mixed
EdgeInst Constrain — Small cap ($0.5B) below institutional reach
SuitabilitySpeculative — Binary industry: Biotechnology
Investment implication
The L1 gate blocked the positive-verdict path: a hard-floor threshold was breached, so dimensional pillars — including Growth at 10.0 could not lift the engine output above the verdict floor.
The strongest dimensions are Growth at 10.0, Value at 9.0, and Sentiment at 8.1; the weakest are Catalyst at 2.8, Quality at 3.5, and Risk (lower is worse) at 3.8. The V9 engine cleared all gates, producing an asymmetric reward-to-risk of 9.62 and an engine sizing output of AVOID.
What would invalidate the thesis
Falsifying conditions — when triggered, the corresponding pillar's thesis is invalidated.
- P1Explosive Revenue Growth
Trip ifRevenue growth falls below 50% YoY for 2 consecutive quarters.
- P2Extreme Cash Burn Rule Of 40 Fail
Trip ifFree cash flow margin rises above -500% of revenue for 2 consecutive quarters.
- P3Overbought Momentum Asymmetric Upside
Trip ifPrice falls below the $9.66 stop-loss level, invalidating the 9.62x asymmetry setup.
- P4Elevated Options Hedging Activity
Trip ifPut/call ratio falls below 1.0, reversing the current elevated hedging posture.
- P5Volatile Earnings Track Record
Trip ifThe company beats EPS estimates in at least 3 of the next 4 quarters, improving on the current 2-of-4 beat rate.